Nine-month Results Remain On Track for Net ProfitAd Hoc Announcement Pursuant to Art. 53 LRGeneva, Switzerland, November 11, 2024-Addex ...

Pharma Two B Ltd. (“Pharma Two B”), a late-clinical stage company that is developing P2B001, an innovative combination product candidate for the treatment of Parkinson’s Disease (“PD”) and Hepion ...

WJX TORONTO, November 11, 2024  Wajax Corporation ("Wajax" or the "Corporation") today announced that Stuart Auld, Chief Financial Officer, will present at the 24th Annual Scotiabank Transportation ...

Corbus Pharmaceuticals still shows promise, with CRB-701 and CRB-601 advancing in clinical trials. Read why CRBP stock is ...

"We are excited to provide an updated assessment of objective response to dordaviprone previously reported in the blinded independent central review (BICR) cohort 1 in recurrent H3 K27M-mutant diffuse ...

EMPOWER-1 and EMPOWER-2 Phase 2 clinical trials did not meet their primary endpoint Emraclidine was well-tolerated with an adverse event profile consistent with ...

This valuable study investigates how the neural representation of individual finger movements changes during the early period of sequence learning. By combining a new method for extracting features ...